PACS GROUP INC (PACS)
US69380Q1076 - Common Stock
Overall PACS gets a fundamental rating of 3 out of 10. We evaluated PACS against 107 industry peers in the Health Care Providers & Services industry. PACS has a bad profitability rating. Also its financial health evaluation is rather negative. PACS has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
PACS had positive earnings in the past year.
1.2 Ratios
PACS has a better Return On Assets (2.90%) than 68.57% of its industry peers.
Looking at the Return On Equity, with a value of 19.73%, PACS belongs to the top of the industry, outperforming 90.48% of the companies in the same industry.
With a Return On Invested Capital value of 4.38%, PACS perfoms like the industry average, outperforming 52.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.9% | ||
| ROE | 19.73% | ||
| ROIC | 4.38% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 3.63%, PACS is in the better half of the industry, outperforming 76.19% of the companies in the same industry.
PACS's Operating Margin of 6.68% is fine compared to the rest of the industry. PACS outperforms 71.43% of its industry peers.
PACS's Gross Margin of 21.33% is in line compared to the rest of the industry. PACS outperforms 41.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.68% | ||
| PM (TTM) | 3.63% | ||
| GM | 21.33% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PACS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for PACS remains at a similar level compared to 1 year ago.
The debt/assets ratio for PACS is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.49, we must say that PACS is in the distress zone and has some risk of bankruptcy.
PACS's Altman-Z score of 1.49 is on the low side compared to the rest of the industry. PACS is outperformed by 60.95% of its industry peers.
PACS has a Debt/Equity ratio of 0.90. This is a neutral value indicating PACS is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.90, PACS is not doing good in the industry: 63.81% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.9 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.49 |
ROIC/WACC0.53
WACC8.33%
2.3 Liquidity
A Current Ratio of 1.71 indicates that PACS should not have too much problems paying its short term obligations.
PACS has a Current ratio of 1.71. This is in the better half of the industry: PACS outperforms 62.86% of its industry peers.
PACS has a Quick Ratio of 1.71. This is a normal value and indicates that PACS is financially healthy and should not expect problems in meeting its short term obligations.
PACS's Quick ratio of 1.71 is fine compared to the rest of the industry. PACS outperforms 65.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.71 | ||
| Quick Ratio | 1.71 |
3. Growth
3.1 Past
PACS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.00%.
PACS shows a strong growth in Revenue. In the last year, the Revenue has grown by 28.47%.
EPS 1Y (TTM)-25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-144.28%
Revenue 1Y (TTM)28.47%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%29.08%
3.2 Future
Based on estimates for the next years, PACS will show a very strong growth in Earnings Per Share. The EPS will grow by 41.62% on average per year.
Based on estimates for the next years, PACS will show a quite strong growth in Revenue. The Revenue will grow by 19.08% on average per year.
EPS Next Y40.21%
EPS Next 2Y54.73%
EPS Next 3Y41.62%
EPS Next 5YN/A
Revenue Next Year29.04%
Revenue Next 2Y23.56%
Revenue Next 3Y19.08%
Revenue Next 5YN/A
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 17.57 indicates a rather expensive valuation of PACS.
PACS's Price/Earnings ratio is a bit cheaper when compared to the industry. PACS is cheaper than 72.38% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.41. PACS is valued slightly cheaper when compared to this.
The Price/Forward Earnings ratio is 7.30, which indicates a rather cheap valuation of PACS.
98.10% of the companies in the same industry are more expensive than PACS, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of PACS to the average of the S&P500 Index (23.69), we can say PACS is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.57 | ||
| Fwd PE | 7.3 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PACS indicates a somewhat cheap valuation: PACS is cheaper than 70.48% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 10.84 |
4.3 Compensation for Growth
PACS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as PACS's earnings are expected to grow with 41.62% in the coming years.
PEG (NY)0.44
PEG (5Y)N/A
EPS Next 2Y54.73%
EPS Next 3Y41.62%
5. Dividend
5.1 Amount
No dividends for PACS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PACS GROUP INC
NYSE:PACS (1/3/2025, 8:04:01 PM)
After market: 13.4705 +0.12 (+0.9%)13.35
+0.42 (+3.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners21.65%
Inst Owner Change65.4%
Ins Owners72.29%
Ins Owner Change-16.67%
Market Cap2.07B
Analysts83.08
Price Target37.74 (182.7%)
Short Float %8.59%
Short Ratio2.21
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)40.28%
Min EPS beat(2)24.18%
Max EPS beat(2)56.37%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)3.83%
Min Revenue beat(2)2.62%
Max Revenue beat(2)5.03%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.83%
PT rev (3m)-9.76%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-15.86%
EPS NY rev (1m)0%
EPS NY rev (3m)6.06%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.6%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.7%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.57 | ||
| Fwd PE | 7.3 | ||
| P/S | 0.67 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.62 | ||
| P/tB | 4.09 | ||
| EV/EBITDA | 10.84 |
EPS(TTM)0.76
EY5.69%
EPS(NY)1.83
Fwd EY13.7%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS20.05
BVpS3.69
TBVpS3.27
PEG (NY)0.44
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.9% | ||
| ROE | 19.73% | ||
| ROCE | 6.06% | ||
| ROIC | 4.38% | ||
| ROICexc | 4.47% | ||
| ROICexgc | 4.56% | ||
| OM | 6.68% | ||
| PM (TTM) | 3.63% | ||
| GM | 21.33% | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.8
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.9 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 2.21 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.71 | ||
| Quick Ratio | 1.71 | ||
| Altman-Z | 1.49 |
F-ScoreN/A
WACC8.33%
ROIC/WACC0.53
Cap/Depr(3y)671.95%
Cap/Depr(5y)N/A
Cap/Sales(3y)4.35%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-144.28%
EPS Next Y40.21%
EPS Next 2Y54.73%
EPS Next 3Y41.62%
EPS Next 5YN/A
Revenue 1Y (TTM)28.47%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%29.08%
Revenue Next Year29.04%
Revenue Next 2Y23.56%
Revenue Next 3Y19.08%
Revenue Next 5YN/A
EBIT growth 1Y-9.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year85.08%
EBIT Next 3Y38.4%
EBIT Next 5YN/A
FCF growth 1Y-74.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.22%
OCF growth 3YN/A
OCF growth 5YN/A